KR101578224B1 - 성기능장애의 치료에서의 테스토스테론과 ｈｔ1ａ 작용제의 용도 - Google Patents

성기능장애의 치료에서의 테스토스테론과 ｈｔ1ａ 작용제의 용도 Download PDF

Info

Publication number
KR101578224B1
KR101578224B1 KR1020097011483A KR20097011483A KR101578224B1 KR 101578224 B1 KR101578224 B1 KR 101578224B1 KR 1020097011483 A KR1020097011483 A KR 1020097011483A KR 20097011483 A KR20097011483 A KR 20097011483A KR 101578224 B1 KR101578224 B1 KR 101578224B1
Authority
KR
South Korea
Prior art keywords
testosterone
ht1a
sexual
ht1a agonist
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097011483A
Other languages
English (en)
Korean (ko)
Other versions
KR20090111802A (ko
Inventor
얀 요한 아드리안 투에텐
요하네스 말티너스 마리아 브로에멀스
로버터스 페트러스 요하네스 데 란제
Original Assignee
이비 아이피 라이브리도스 비.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이비 아이피 라이브리도스 비.브이. filed Critical 이비 아이피 라이브리도스 비.브이.
Publication of KR20090111802A publication Critical patent/KR20090111802A/ko
Application granted granted Critical
Publication of KR101578224B1 publication Critical patent/KR101578224B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
KR1020097011483A 2006-11-03 2007-11-02 성기능장애의 치료에서의 테스토스테론과 ｈｔ1ａ 작용제의 용도 Expired - Fee Related KR101578224B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06076976A EP1925307A1 (en) 2006-11-03 2006-11-03 Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
EP06076976.7 2006-11-03
PCT/NL2007/050533 WO2008054213A2 (en) 2006-11-03 2007-11-02 Use of testosterone and a 5-ht1a agonist in the treatment of sexual dysfunction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020157022168A Division KR20150099620A (ko) 2006-11-03 2007-11-02 성기능장애의 치료에서의 테스토스테론과 ｈｔ1ａ 작용제의 용도

Publications (2)

Publication Number Publication Date
KR20090111802A KR20090111802A (ko) 2009-10-27
KR101578224B1 true KR101578224B1 (ko) 2015-12-16

Family

ID=37846101

Family Applications (6)

Application Number Title Priority Date Filing Date
KR1020097011483A Expired - Fee Related KR101578224B1 (ko) 2006-11-03 2007-11-02 성기능장애의 치료에서의 테스토스테론과 ｈｔ1ａ 작용제의 용도
KR1020097011486A Ceased KR20090111803A (ko) 2006-11-03 2007-11-02 성기능 장애의 치료에서의 임의로 5-ｈｔ1ａ 작용제와 조합된, 3-알파-안드로스탄디올의 용도
KR20157004613A Ceased KR20150038251A (ko) 2006-11-03 2007-11-02 성기능 장애의 치료에서의 임의로 5-ｈｔ1ａ 작용제와 조합된, 3-알파-안드로스탄디올의 용도
KR1020097011485A Ceased KR20090115113A (ko) 2006-11-03 2007-11-02 성 기능장애의 치료에서, 임의적으로 ｐｄｅ5 억제제와 조합된, 3-알파-안드로스탄디올의 용도
KR1020167028902A Expired - Fee Related KR101796887B1 (ko) 2006-11-03 2007-11-02 성기능장애의 치료에서의 테스토스테론과 ｈｔ1ａ 작용제의 용도
KR1020157022168A Ceased KR20150099620A (ko) 2006-11-03 2007-11-02 성기능장애의 치료에서의 테스토스테론과 ｈｔ1ａ 작용제의 용도

Family Applications After (5)

Application Number Title Priority Date Filing Date
KR1020097011486A Ceased KR20090111803A (ko) 2006-11-03 2007-11-02 성기능 장애의 치료에서의 임의로 5-ｈｔ1ａ 작용제와 조합된, 3-알파-안드로스탄디올의 용도
KR20157004613A Ceased KR20150038251A (ko) 2006-11-03 2007-11-02 성기능 장애의 치료에서의 임의로 5-ｈｔ1ａ 작용제와 조합된, 3-알파-안드로스탄디올의 용도
KR1020097011485A Ceased KR20090115113A (ko) 2006-11-03 2007-11-02 성 기능장애의 치료에서, 임의적으로 ｐｄｅ5 억제제와 조합된, 3-알파-안드로스탄디올의 용도
KR1020167028902A Expired - Fee Related KR101796887B1 (ko) 2006-11-03 2007-11-02 성기능장애의 치료에서의 테스토스테론과 ｈｔ1ａ 작용제의 용도
KR1020157022168A Ceased KR20150099620A (ko) 2006-11-03 2007-11-02 성기능장애의 치료에서의 테스토스테론과 ｈｔ1ａ 작용제의 용도

Country Status (27)

Country Link
US (10) US8575139B2 (https=)
EP (5) EP1925307A1 (https=)
JP (8) JP2010509211A (https=)
KR (6) KR101578224B1 (https=)
CN (6) CN104524580A (https=)
AU (3) AU2007314736B2 (https=)
BR (3) BRPI0718396A2 (https=)
CA (3) CA2668320C (https=)
CY (1) CY1117191T1 (https=)
DK (1) DK2086544T3 (https=)
ES (1) ES2561946T3 (https=)
HR (1) HRP20160108T1 (https=)
HU (1) HUE026752T2 (https=)
IL (5) IL198459A (https=)
ME (1) ME02410B (https=)
MX (3) MX2009004695A (https=)
NO (3) NO343597B1 (https=)
NZ (3) NZ577390A (https=)
PH (2) PH12014501440A1 (https=)
PL (1) PL2086544T3 (https=)
PT (1) PT2086544E (https=)
RS (1) RS54541B1 (https=)
RU (4) RU2463054C2 (https=)
SI (1) SI2086544T1 (https=)
UA (4) UA100119C2 (https=)
WO (3) WO2008054213A2 (https=)
ZA (3) ZA200903837B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1750766B1 (en) 2004-05-11 2013-07-03 Emotional Brain B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
EP2266567A1 (en) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of cetrorelix in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
EP2266568A1 (en) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
SG10201606751XA (en) * 2011-05-13 2016-10-28 Eb Ip Hybritabs B V Drug Delivery System
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
JP5828923B2 (ja) 2014-01-30 2015-12-09 国立大学法人高知大学 ニッケル粉の製造方法
WO2015125650A1 (ja) 2014-02-21 2015-08-27 国立大学法人高知大学 ニッケル粉の製造方法
JP6406613B2 (ja) 2014-04-15 2018-10-17 住友金属鉱山株式会社 含有する炭素及び硫黄の濃度を低減するニッケル粉の製造方法
CN103947533B (zh) * 2014-05-15 2015-12-16 青岛理工大学 生长环境可控的磁化水工厂化豆芽菜生产系统
RU2600845C2 (ru) 2014-07-04 2016-10-27 Общество С Ограниченной Ответственностью "Консорциум-Пик" Применение производных оксатриазолий-5-олата для лечения сексуальных расстройств
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065158A1 (en) * 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
US20050152956A1 (en) * 2000-08-30 2005-07-14 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3251436A (en) * 1965-03-16 1966-05-17 Dayton Steel Foundry Co Spot-type disk brake
US3976776A (en) 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
AU577802B2 (en) * 1983-10-17 1988-10-06 Duphar International Research B.V. Blood-pressure lowering piperazine derivatives
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4640921A (en) * 1986-02-04 1987-02-03 Bristol-Myers Treatment of sexual dysfunction with buspirone
US5015646A (en) * 1987-08-28 1991-05-14 Bristol-Myers Squibb Co. Pharmaceutically useful polymorphic modification of buspirone
US4877774A (en) 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones
CA1335106C (en) * 1989-02-27 1995-04-04 John Mehnert Schaus Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes
US5447912A (en) 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US5431922A (en) * 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
JP3455544B2 (ja) 1994-06-02 2003-10-14 リガ ダン 抗ストレス剤、抗機能障害剤および抗老化剤、ならびに該薬剤の製造法
RU2152787C2 (ru) * 1994-06-02 2000-07-20 Дан Рига Лекарство против стресса, против снижения уровня активности и против старения и способ его получения
AU4844396A (en) 1995-03-01 1996-09-18 Kyowa Hakko Kogyo Co. Ltd. Imidazoquinazoline derivatives
CA2215307A1 (en) 1995-03-14 1996-09-19 Vivus, Incorporated Pharmaceutical compositions and kits for preventing erectile dysfunction
US5731339A (en) 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
CA2219082A1 (en) 1995-05-15 1996-11-21 Beth Israel Deaconess Medical Center, Inc. Use of dihydrotestosterone compounds for treating male sexual dysfunction
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US6251436B1 (en) * 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US6242198B1 (en) 1996-07-25 2001-06-05 Cambridge Neuroscience, Inc. Methods of treatment of eye trauma and disorders
AU756136B2 (en) 1997-06-23 2003-01-02 Queen's University At Kingston Microdose therapy
US20040014761A1 (en) 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US5877216A (en) * 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
CA2306837C (en) 1997-10-28 2007-05-08 Vivus, Inc. Treatment of female sexual dysfunction
US20020013304A1 (en) * 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US6246436B1 (en) 1997-11-03 2001-06-12 Agilent Technologies, Inc Adjustable gain active pixel sensor
TW542719B (en) * 1998-02-23 2003-07-21 Pfizer Res & Dev Method of treating impotence due to spinal cord injury
US6403605B1 (en) 1998-05-29 2002-06-11 Queen's University At Kingston Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
UA67802C2 (uk) 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US6613768B1 (en) 1999-04-30 2003-09-02 Lilly Icos Llc Treatment of female arousal disorder
US6632419B2 (en) * 1999-05-04 2003-10-14 Aradigm Corporation Increasing libido in humans via acute testosterone administration
US7258850B2 (en) 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
US6428769B1 (en) 1999-05-04 2002-08-06 Aradigm Corporation Acute testosterone administration
EP1207902A2 (de) 1999-06-17 2002-05-29 Pharmacia AB VERWENDUNG VON WACHSTUMSHORMON (hGH) ZUR THERAPIE SEXUELLER FUNKTIONSSTÖRUNGEN
RU2180591C2 (ru) 1999-12-24 2002-03-20 Государственное научное предприятие Московский научно-исследовательский институт психиатрии МЗ РФ Средство для лечения сексуальных дисфункций у мужчин
DE10016548A1 (de) * 2000-04-03 2001-10-11 Bayer Ag Polyurethan-Dispersionen
US6313172B1 (en) 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US6242436B1 (en) * 2000-06-15 2001-06-05 William Charles Llewellyn Use of 5alpha-androstanediol or 5alpha-androstanedione to increase dihydrotestosterone levels in humans
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
ES2341090T3 (es) 2000-08-30 2010-06-15 Unimed Pharmaceuticals, Llc Procedimiento para tratar la disfuncion erectil y aumentar la libido en hombres.
US20030139384A1 (en) 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
ATE361060T1 (de) 2000-09-29 2007-05-15 Solvay Pharm Bv Ionenstärkenunabhängige pharmazeutische formulierung mit verzögerter freisetzung
US20060287335A1 (en) 2000-11-28 2006-12-21 Wyeth Serotonergic agents for treating sexual dysfunction
EP1347750A1 (en) * 2000-12-15 2003-10-01 Pfizer Limited Treatment of male sexual dysfunction
US20020107230A1 (en) 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
WO2002069906A2 (en) 2001-03-06 2002-09-12 Cellegy Pharmaceuticals, Inc. Compounds and methods for the treatment of urogenital disorders
IL157009A0 (en) 2001-03-28 2004-02-08 Pfizer N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad
EP1260225A1 (en) * 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
US20030027804A1 (en) * 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
US20030022875A1 (en) 2001-07-27 2003-01-30 Wilson Leland F. As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US20040259852A1 (en) 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
BRPI0411985A (pt) * 2003-07-16 2006-08-29 Pfizer tratamento da disfunção sexual
ATE319426T1 (de) * 2003-11-11 2006-03-15 Mattern Udo Nasenformulierung mit kontrollierter freisetzung von sexualhormonen
WO2005094827A1 (en) * 2004-03-30 2005-10-13 Kestrel Pharmaceuticals Inc. Methods for treating sexual dysfunction
AU2005235422B2 (en) * 2004-04-22 2011-08-11 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for the treatment of sexual disorders II
EP1750766B1 (en) * 2004-05-11 2013-07-03 Emotional Brain B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
EP1868590A4 (en) * 2005-04-13 2012-08-29 Unimed Pharmaceuticals Inc PROCESS FOR INCREASING TESTOSTERONE AND CORRESPONDING STEROID CONCENTRATIONS IN WOMEN
WO2006127057A1 (en) 2005-05-24 2006-11-30 Lyle Corporate Drvelopment, Inc. Non-systematic vaginal administration of estrogen and an androgen for the treatment of sexual dysfunction
US8067399B2 (en) 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
WO2007054791A2 (en) 2005-11-08 2007-05-18 L'oréal Androgen glucuronides as markers of androgenic activity
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
NZ584363A (en) 2007-11-28 2012-11-30 Ucb Pharma Gmbh Drug formulations of Rotigotine which comprise the thermodynamically stable polymorphic form 2

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050152956A1 (en) * 2000-08-30 2005-07-14 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20050065158A1 (en) * 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction

Also Published As

Publication number Publication date
WO2008054213A2 (en) 2008-05-08
ZA200903835B (en) 2010-10-27
AU2007314736A1 (en) 2008-05-08
ZA200903836B (en) 2010-08-25
KR20090111803A (ko) 2009-10-27
WO2008054214A2 (en) 2008-05-08
HK1135038A1 (en) 2010-05-28
US20100093680A1 (en) 2010-04-15
AU2007314734A1 (en) 2008-05-08
IL248563A0 (en) 2016-12-29
US20170157142A1 (en) 2017-06-08
EP2086548A2 (en) 2009-08-12
MX2009004696A (es) 2009-06-05
JP2010509211A (ja) 2010-03-25
IL248563B (en) 2018-11-29
JP6357131B2 (ja) 2018-07-11
JP2010509213A (ja) 2010-03-25
DK2086544T3 (en) 2016-02-08
RU2646447C2 (ru) 2018-03-05
CN104524580A (zh) 2015-04-22
RU2463054C2 (ru) 2012-10-10
US10314848B2 (en) 2019-06-11
PH12014501821B1 (en) 2016-02-01
CN103599536A (zh) 2014-02-26
US20140038929A1 (en) 2014-02-06
US20100160270A1 (en) 2010-06-24
JP2017132809A (ja) 2017-08-03
KR101796887B1 (ko) 2017-11-10
EP2086544A2 (en) 2009-08-12
US8575139B2 (en) 2013-11-05
CN101563086B (zh) 2013-11-27
WO2008054215A2 (en) 2008-05-08
UA115647C2 (uk) 2017-12-11
US20120277200A1 (en) 2012-11-01
PT2086544E (pt) 2016-03-17
CN101557812A (zh) 2009-10-14
IL198460A (en) 2016-11-30
IL198460A0 (en) 2010-02-17
IL198461A (en) 2017-08-31
NO20092143L (no) 2009-07-02
WO2008054214A3 (en) 2009-04-09
RU2464027C2 (ru) 2012-10-20
RU2009120992A (ru) 2010-12-10
JP2014055142A (ja) 2014-03-27
RU2012125827A (ru) 2013-12-27
MX2009004695A (es) 2009-06-05
NO20092146L (no) 2009-07-21
AU2007314735B2 (en) 2014-01-16
CY1117191T1 (el) 2017-04-05
US8648060B2 (en) 2014-02-11
US8653051B2 (en) 2014-02-18
PH12014501440A1 (en) 2016-02-01
RU2491073C2 (ru) 2013-08-27
US9211334B2 (en) 2015-12-15
CA2668320C (en) 2014-06-10
US9597335B2 (en) 2017-03-21
CA2668320A1 (en) 2008-05-08
AU2007314736B2 (en) 2014-01-23
BRPI0718396A2 (pt) 2013-11-26
RU2009120990A (ru) 2010-12-10
KR20090111802A (ko) 2009-10-27
IL198461A0 (en) 2010-02-17
HUE026752T2 (en) 2016-07-28
UA100119C2 (uk) 2012-11-26
WO2008054213A3 (en) 2009-04-09
CN103381270A (zh) 2013-11-06
UA101948C2 (uk) 2013-05-27
NZ577393A (en) 2012-11-30
US20140121190A1 (en) 2014-05-01
CA2668316A1 (en) 2008-05-08
ES2561946T3 (es) 2016-03-01
US20190262359A1 (en) 2019-08-29
KR20160124246A (ko) 2016-10-26
CA2668316C (en) 2014-06-10
UA103592C2 (uk) 2013-11-11
EP1925307A1 (en) 2008-05-28
NZ577390A (en) 2012-12-21
IL237786A0 (en) 2015-05-31
ZA200903837B (en) 2010-08-25
JP2010509212A (ja) 2010-03-25
US8669242B2 (en) 2014-03-11
SI2086544T1 (sl) 2016-04-29
MX2009004693A (es) 2009-06-05
KR20150038251A (ko) 2015-04-08
NO20092145L (no) 2009-07-21
WO2008054215A3 (en) 2009-04-09
NO343597B1 (no) 2019-04-08
KR20090115113A (ko) 2009-11-04
EP2086545A2 (en) 2009-08-12
IL198459A0 (en) 2010-02-17
CN101563086A (zh) 2009-10-21
CA2668317A1 (en) 2008-05-08
BRPI0717963A2 (pt) 2013-11-05
JP2015157849A (ja) 2015-09-03
JP2014001235A (ja) 2014-01-09
PH12014501821A1 (en) 2016-02-01
NZ577392A (en) 2012-11-30
US20160082018A1 (en) 2016-03-24
KR20150099620A (ko) 2015-08-31
BRPI0717856A2 (pt) 2013-10-29
ME02410B (me) 2016-09-20
US20100152145A1 (en) 2010-06-17
IL198459A (en) 2016-11-30
PL2086544T3 (pl) 2016-07-29
RS54541B1 (sr) 2016-06-30
AU2007314734B2 (en) 2014-01-30
CN101573119A (zh) 2009-11-04
JP2014111608A (ja) 2014-06-19
HRP20160108T1 (hr) 2016-03-25
EP2937086A1 (en) 2015-10-28
CA2668317C (en) 2016-02-09
RU2009120988A (ru) 2010-12-10
EP2086544B1 (en) 2015-12-23
AU2007314735A1 (en) 2008-05-08
JP5748238B2 (ja) 2015-07-15
US20140121189A1 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
KR101578224B1 (ko) 성기능장애의 치료에서의 테스토스테론과 ｈｔ1ａ 작용제의 용도
HK1190945A (en) Use of testosterone and a 5-ht1a agonist in the treatment of sexual dysfunction
HK1135038B (en) Use of testosterone and a 5-ht1a agonist in the treatment of sexual dysfunction
HK1194657A (en) Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20190425

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20221211

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20221211